Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 24 of 24 entries
View as:

Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists

Phase: N/A Priority: Normal
NCT ID: NCT02126579 Org: User:
Start: 05/01/14 End: 05/05/21 Due: 05/05/22

Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00912418 Org: User:
Start: 05/01/00 End: 10/09/02 Due: 10/09/03

Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01532960 Org: User:
Start: 07/31/12 End: 09/30/15 Due: 09/30/16

Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)

Phase: N/A Priority: Normal
NCT ID: NCT04364230 Org: User:
Start: 09/28/20 End: 03/14/24 Due: 03/14/25

Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00892567 Org: User:
Start: 05/31/09 End: 02/29/12 Due: 02/28/13

Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02305186 Org: User:
Start: 03/31/15 End: 12/31/22 Due: 12/31/23

Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI

Phase: N/A Priority: Normal
NCT ID: NCT01425749 Org: User:
Start: 06/30/11 End: 10/31/15 Due: 10/31/16

Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00091286 Org: User:
Start: 03/24/03 End: 02/15/08 Due: 02/15/09

A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT02385669 Org: User:
Start: 04/30/15 End: 09/18/19 Due: 09/18/20

Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00977145 Org: User:
Start: 11/30/09 End: - Due: -

Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04116320 Org: User:
Start: 11/21/19 End: 02/29/24 Due: 02/28/25

Vaccine Therapy in Treating Patients With Advanced Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00705640 Org: User:
Start: 05/31/08 End: - Due: -

Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT03617328 Org: User:
Start: 11/13/18 End: 01/19/24 Due: 01/19/25

Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00373217 Org: User:
Start: 04/13/06 End: 02/07/08 Due: 02/07/09

Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab

Phase: N/A Priority: Normal
NCT ID: NCT02515227 Org: User:
Start: 10/06/16 End: 03/14/20 Due: 03/14/21

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00118274 Org: User:
Start: 03/31/05 End: 02/28/10 Due: 02/28/11

Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00089193 Org: User:
Start: 09/30/03 End: - Due: -

A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib

Phase: N/A Priority: Normal
NCT ID: NCT02382549 Org: User:
Start: 04/30/16 End: 02/28/22 Due: 02/28/23

Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT01846143 Org: User:
Start: 05/31/13 End: 11/30/15 Due: 11/30/16

Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT02425306 Org: User:
Start: 05/12/15 End: 01/08/18 Due: 01/08/19

A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients

Phase: N/A Priority: Normal
NCT ID: NCT01585350 Org: User:
Start: 10/31/12 End: 10/31/14 Due: 10/31/15

Excision of Lymph Node Trial (EXCILYNT) (Mel69)

Phase: N/A Priority: Normal
NCT ID: NCT05839912 Org: User:
Start: 09/06/23 End: 09/01/28 Due: 09/01/29

Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00118313 Org: User:
Start: 11/04/04 End: 07/28/06 Due: 07/28/07

Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00938223 Org: User:
Start: 08/31/00 End: - Due: -